Skip to main content

Levetiracetam reduces myoclonus in corticobasal degeneration: report of two cases

Abstract

Levetiracetam (LEV) has been shown to suppress myoclonus of various origins. Corticobasal degeneration (CBD), a progressive neurodegenerative disorder with Parkinsonian syndrome, is frequently accompanied by myoclonus. We investigated the effect of LEV on myoclonus in two CBD patients. LEV remarkably decreased the myoclonic activity in both patients already at 1,500 mg/day dose. This is the first report on LEV alleviating myoclonus in CBD. Our data indicate that it might be worthwhile to assess this effect in an appropriately designed study.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  • Agarwal P, Frucht SJ (2003) Myoclonus. Curr Opin Neurol 16:515–521

    Article  PubMed  Google Scholar 

  • Beran RG, Berkovic SF, Black AB et al (2005) Efficacy of levetiracetam 1000–3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open label single-arm study. Epilepsy Res 63:1–9

    Article  CAS  PubMed  Google Scholar 

  • Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U, The Levetiracetam N01057 Study Group (2007) Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 69:1751–1760

    Article  CAS  PubMed  Google Scholar 

  • Boeve BF, Lamg AE, Litvan I (2003) Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 54:S15–S19

    Article  PubMed  Google Scholar 

  • Crest C, Dupont S, Leguern E et al (2004) Levetiracetam in progressive myoclonic epilepsy. An exploratory study in 9 patients. Neurology 62:640–643

    CAS  PubMed  Google Scholar 

  • D’Amelio M, Callari G, Gammino M et al (2005) Levetiracetam in the treatment of vascular chorea: a case report. Eur J Clin Pharmacol 60:835–836

    Article  PubMed  Google Scholar 

  • de Tommaso M, di Fruscolo O, Sciruicchio V et al (2005) Efficacy of levetiracetam in Huntington disease. Clin Neuropharmacol 28:280–284

    Article  PubMed  Google Scholar 

  • Fahn S (2002) Overview, history, and classification of myoclonus. Adv Neurol 89:13–17

    PubMed  Google Scholar 

  • Frucht S, Leurgans S, Hallet M et al (2000) The Unified Myoclonus Rating Scale (UMRS): a statistically validated clinical rating instrument for evaluating patients with myoclonus. Mov Disord 15(Suppl 3):107

    Google Scholar 

  • Grisoli M, Fetoni V, Savoiardo M et al (1995) MRI in corticobasal degeneration. Eur J Neurol 2:547–552

    Google Scholar 

  • Grosse P, Kühn A, Cordivari C, Brown P (2003) Coherence analysis in the myoclonus of corticobasal degeneration. Mov Disord 18:1345–1350

    Article  PubMed  Google Scholar 

  • Keswani SC, Kossoff EH, Krauss GL et al (2002) Amelioration of spinal myoclonus with levetiracetam. J Neurol Neurosurg Psychiatry 73:457–458

    Article  CAS  PubMed  Google Scholar 

  • Kompoliti K, Goetz CG, Boeve BF et al (1998) Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 55:957–961

    Article  CAS  PubMed  Google Scholar 

  • Krauss GL, Bergin MB, Kramer RE et al (2001) Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 56:411–412

    CAS  PubMed  Google Scholar 

  • Litvan I, Bhatia KP, Burn DJ et al (2003) SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 18:467–486

    Article  PubMed  Google Scholar 

  • Lynch BA, Lambeng N, Nocka K et al (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracteam. Proc Natl Acad Sci USA 101:9861–9866

    Article  CAS  PubMed  Google Scholar 

  • Lyons KE, Pahwa R (2006) Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. Clin Neuropharmacol 29:148–153

    Article  CAS  PubMed  Google Scholar 

  • Margineanu DG, Klitgaard H (2000) Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res 42:281–285

    Article  CAS  PubMed  Google Scholar 

  • Meco G, Fabrizio E, Epifanio A et al (2006) Levetiracetam in tardive dyskinesia. Clin Neuropharmacol 29:265–268

    Article  CAS  PubMed  Google Scholar 

  • Mima T, Nagamini T, Ikeda A et al (1998) Pathogenesis of cortical myoclonus studied by magnetoencephalography. Ann Neurol 43:598–607

    Article  CAS  PubMed  Google Scholar 

  • Riley DE, Lang AE, Lewis A et al (1990) Cortical-basal ganglionic degeneration. Neurology 40:1203–1212

    CAS  PubMed  Google Scholar 

  • Sawle GV, Brooks DJ, Marsden CD et al (1991) Corticobasal degeneration: a unique pattern of regional cortical oxygen metabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain 114:541–556

    Article  PubMed  Google Scholar 

  • Shibasaki H, Kuroiwa Y (1975) Electroencephalographic correlates of myoclonus. Electroencephalogr Clin Neurophysiol 36:455–463

    Google Scholar 

  • Storey E, Lichtenstein M, Desmond P et al (1995) Clinical features and SPECT scanning in presumed corticobasal ganglionic degeneration. J Clin Neurosci 2:321–328

    Article  CAS  PubMed  Google Scholar 

  • Striano P, Manganelli F, Boccella P et al (2005) Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord 20:1610–1614

    Article  PubMed  Google Scholar 

  • Thompson PD, Day BL, Rothwell JC et al (1994) The myoclonus in corticobasal degeneration. Brain 117:1197–1207

    Article  PubMed  Google Scholar 

  • Wadia PM, Lang AE (2007) The many faces of corticobasal degeneration. Parkinsonism Relat Disord 13:S336–S340

    Article  PubMed  Google Scholar 

  • Zesiewicz TA, Louis ED, Sulivan KL et al (2004) Substantial improvement in a Meige’s syndrome patient with levetiracteam treatment. Mov Disord 19:1518–1521

    Article  PubMed  Google Scholar 

Download references

Conflict of interest statement

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tibor Kovács.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kovács, T., Farsang, M., Vitaszil, E. et al. Levetiracetam reduces myoclonus in corticobasal degeneration: report of two cases. J Neural Transm 116, 1631 (2009). https://doi.org/10.1007/s00702-009-0301-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00702-009-0301-2

Keywords

  • Levetiracetam
  • Myoclonus
  • Corticobasal degeneration
  • Parkinsonian syndrome